Document is current
Any future updates will be listed below
-
Authors
Pacini, Clare https://orcid.org/0000-0001-7791-0940
Dempster, Joshua M. https://orcid.org/0000-0002-3634-9576
Boyle, Isabella https://orcid.org/0000-0002-8138-1225
Gonçalves, Emanuel https://orcid.org/0000-0002-9967-5205
Najgebauer, Hanna
Karakoc, Emre
van der Meer, Dieudonne
Barthorpe, Andrew
Lightfoot, Howard
Jaaks, Patricia
McFarland, James M. https://orcid.org/0000-0001-9978-480X
Garnett, Mathew J. https://orcid.org/0000-0002-2618-4237
Tsherniak, Aviad https://orcid.org/0000-0002-3797-1877
Iorio, Francesco https://orcid.org/0000-0001-7063-8913
-
Funding
Funding for this research was provided by:
Open Targets: project number OTAR2-55
- License Information
-
More Information
Article History
Received: 18 December 2020
Accepted: 18 February 2021
First Online: 12 March 2021
Competing interests
: M.J.G. and F.I. receive funding from Open Targets, a public-private initiative involving academia and industry. M.J.G. receives funding from AstraZeneca and performs consultancy for Sanofi. F.I. performs consultancy for the joint CRUK—AstraZeneca Functional Genomics Center. A.T. is a consultant for Tango Therapeutics and Cedilla Therapeutics. J.M.D., J.M., and A.T. receive funding from the Cancer Dependency Map Consortium, but no consortium member was involved in or influenced this study. All the other authors declare no competing interests.
